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Summary 
The clinical course of pituitary adenoma can be highly variable.  Aggressive pituitary tumours may 
require multimodal therapy with multiple operations.  Even standard pituitary adenomas exhibit 
relatively high long term recurrence rates and delayed intervention is often required.  The 
indications for revision surgery in the endoscopic era are expanding for both functioning and non-
functioning tumours, including access to the cavernous sinus and intracranial compartments.  
Although revision surgery can be challenging, it has been demonstrated to be both safe and 
effective.   The question of the use of early radiotherapy in pituitary adenoma remains controversial.  
Our increasing understanding of pituitary tumour biology facilitates individualised treatment and 
surveillance protocols, with early intervention in high risk adenoma subtypes.  In this review we 
discuss the treatment options for recurring pituitary tumours and focus on the role of revision 
surgery. 
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Introduction 
Pituitary adenomas are benign, slow growing neoplasms in the majority of cases, with an incidence 
of clinically relevant tumours of 4-7 per 100,000 annually 1,2.  Surgery is usually the first line 
treatment for larger non-functioning adenomas, where there is compression of the optic apparatus 
and the majority of functioning tumours, with the exception of prolactinoma.  However, even in the 
setting of complete surgical resection, there is a high long term recurrence rate of approximately 7 -
12% at 10 years3,4.  Often a complete resection at first surgery may not be achievable due to 
anatomical limitations and in these cases progression or recurrence is often inevitable, reported in 
53% of those with extrasellar residual tissue at 5 years and over 80% at 10 years4. 
Additionally, there is a subset of histologically aggressive adenomas which display early and multiple 
recurrences despite multimodal therapy.  The prevalence of aggressive pituitary adenoma is not 
known and furthermore, the exact definition of these tumours in the literature has been variable.   
There is currently little international consensus on the management of either recurrent pituitary 
adenoma or aggressive pituitary adenoma, particularly on the timing of revision surgery versus early 
or late radiotherapy and the use of chemotherapy, such as temozolomide.  Data on the efficacy and 
safety of revision endoscopic pituitary surgery is emerging but questions remain on the potential 
impact of radiotherapy in the modern era on long term outcomes, both endocrinological and 
surgical. 
This review aims to highlight the advantages and limitations of revision endoscopic pituitary surgery, 
identify ‘at risk’ patients who may require multiple interventions or multimodal therapy and review 
current guidelines on management, in order to provide an evidence base to guide clinical practice in 
the multidisciplinary setting.  
 
Identifying patients at risk of recurrence 
The overall risk of recurrence after pituitary surgery is reported between 30-50% at 5 to 10 years 5–8.  
Complete resection of tumour at first surgery  is reported in 69% of patients in endoscopic series and 
64.5% in microscopic series, based on post-operative MR imaging 9.  Even in the setting of 
radiologically confirmed complete resection of a pituitary adenoma, there is a recognised risk of long 
term recurrence.  Reddy et al reported recurrence in 6.9% of patients with a complete resection at a 
mean of 9.1 years.  Importantly in this study, 20% of re-growths occurred after 10 years of follow-up.  
It is clear that in these cases long term and likely lifelong observation alone is the management 
strategy of choice, with the potential for repeat surgery should recurrence occur.  However there are 
high relapse rates associated with an incomplete resection; these are dependent on the volume of 
residual disease, with 15% of intrasellar remnant tumours growing within 5 years compared to 51% 
of extrasellar residual 8.  This has led some centres to adopt routine post-operative radiotherapy 
where there is residual tumour8.   
Anatomical limitations to complete resection 
The ability to achieve a complete resection of tumour is dependent upon several factors, including 
tumour consistency and invasiveness.  Many radiological features are markers of poor surgical 
outcome, such as multi-lobulated giant adenoma, bony invasion and cavernous sinus involvement.   
The modified Knosp grade is a useful tool to predict tumour resection rates for both functioning and 
non-functioning adenoma (Table1, Figure 1)10.  It depicts the relationship of the adenoma to the 
carotid artery  and was first described by  Knosp et al in 1993 11.  This was updated in 2015 to include 
endoscopic evaluation of the extent of true cavernous sinus invasion and correlated to resection 
rates,  Micko et al demonstrated that a radiological grade 3A adenoma extending into the superior 
compartment of the cavernous sinus was associated with true breach of the cavernous sinus wall in 
only 26.5% and a complete resection was achieved in 85% 10.  In contrast, grade 3B adenomas 
involve the inferior compartment of the cavernous sinus and are truly invasive with breach of the 
cavernous sinus wall in 70%, and a significantly lower complete resection rate of 64%.  However, 
grade 4 adenomas completely encase the internal carotid artery and cavernous sinus structures and 
complete resection of these tumours was 0% in this series (Figure 1).  Additionally, radiologically 
higher grade adenomas tended to display a higher proliferation index (MIB-1 or Ki-67) on histology 
than lower grade tumours, indicating that radiological extension is a function of potentially 
aggressive tumour biology.  
Aggressive pituitary adenoma 
As demonstrated, the majority of pituitary adenomas display benign characteristics with a slow 
relapse rate over many years and anatomical limitations to surgical resection govern the natural 
history.   However, there are subtypes of adenoma that demonstrate rapid recurrence and 
resistance to treatment.  The World Health Organisation classification of pituitary tumours was 
updated in 2017, with adenoma classification now based on cell lineage from immunohistochemistry 
and pituitary transcription factors12.  A major change has been to abandon the term ‘atypical 
adenoma’.  Previously an atypical adenoma was defined as an adenoma with a Ki-67 (or MIB-1) 
index greater than 3%, with features of invasive growth and denoted a tumour with a propensity for 
early recurrence.  Atypical adenomas were reported to account for 3-15% of cases 13,14.  However, 
the term has been used variably in the literature with the cut-off values for Ki-67 varying among 
different centres, hence the reported behaviour of so-called atypical adenoma is difficult to 
interpret. Additionally, using a Ki-67 threshold of 3% meant that evidence for aggressive behaviour 
was conflicting, with little difference seen in recurrence rates 15.  Many centres consider a Ki-67 of 7-
10% more clinically relevant for prediction of aggressive behaviour 16.  In the current classification, 
whilst Ki-67 remains an important marker of aggressive behaviour, no threshold value is defined and 
additional evidence of tumour invasion (cavernous sinus or clival invasion) should also be considered 
as a marker of clinically aggressive behaviour (Table 2).     
Importantly, several adenoma variants are noted to have more aggressive clinical behaviour, 
including the sparsely granulated somatotroph adenoma, silent corticotroph adenoma and the new 
entity of the plurihormonal PIT-1 positive adenoma, previously silent subtype 3 adenoma (Table 3). 
 
 
The role of revision surgery 
The role of repeat surgery in recurrent adenoma is not well studied.  The widespread adoption of the 
endoscopic approach has recently increased focus on the potential to maximise tumour resection, 
due to the improved field of view, better illumination, improvement of identification of critical 
neurovascular structures and normal pituitary gland, plus the ability to access the cavernous sinus 
using angled endoscopes.  A factor associated with a high rate of residual adenoma after microscopic 
approaches is the limited sphenoid and sellar bony exposure, with poor access to the sellar and 
suprasellar region 17 .  With an endoscopic approach there is wide resection of the sellar floor, 
exposure of the cavernous sinus walls and with an expanded approach, excellent visualisation of the 
suprasellar cistern and optic apparatus.  However, revision pituitary surgery is challenging.  The 
anatomy can be distorted by scar tissue, particularly after prior endoscopic approaches.  Anatomical 
planes and landmarks tend to be better preserved after a prior microscopic approach and some 
authors have demonstrated better outcomes in revision surgery after a prior microscopic approach 
18,19.   
Prior radiotherapy can de-vascularise local tissue leading to limited options for skull base 
reconstruction to prevent post-operative CSF leak2021.  It may also contribute to optic nerve 
tethering, which is frequently seen after prior resection of large non-functioning adenomas, with a 
higher risk of post-operative visual decline after revision surgery in our experience.  Additionally, 
tumour residuum is often in unfavourable anatomical locations, but in experienced pituitary centres 
many such adenomas can be resected surgically using an expanded endoscopic approach prior to 
considering other treatment options.  This highlights the need for tertiary pituitary centres of 
excellence with dedicated pituitary surgeons 22.  The indications for revision surgery are outlined in 
Table 4. 
Overall the rates of gross total resection (GTR) after revision surgery are lower than primary surgery 
regardless of the approach, with reported rates of 46.6%-53.5% in revision surgery compared to 69-
71% in primary surgery 23.  The current experience on outcomes for revision surgery using the 
endoscopic approach is summarized in Table 5.  Do et al reported 61 patients who underwent 
revision endoscopic surgery 19. GTR was achieved in 51.7% of cases.  The cavernous sinus was 
involved in 38%.  In those with Knosp grade 0-2 the GTR rate was 70.3% and for those Knosp grade 
3-4, the GTR rate was 21.7%.  CSF leak occurred in 4.9% and 2 patients (3.2%) had a post-operative 
haematoma with visual deterioration.  However, pre-operative visual defects improved or stabilized 
in 95%.  New anterior hypopituitarism occurred in 14.7% and Diabetes Insipidus (DI) in 4.9%.  When 
compared to primary endoscopic surgery, a meta-analysis of post operative complications in revision 
endoscopic transsphenoidal surgery demonstrated a CSF leak  rate of 7%, vascular complications in 
1.5%, DI in 2.31% and anterior hypopituitarism in 8.5% 9.  In a comprehensive analysis of morbidity in 
repeat transsphenoidal surgery, Jahangiri et al reported outcomes in 108 revision procedures, 
compared to 907 primary procedures 21.  There was no significant difference in length of stay (2.5 
days in primary procedures vs 2.3 days), new onset hypopituitarism (19% vs 7%) or post-operative 
hyponatremia.  However, DI occurred in 35% of revision procedures compared to 13% of primary 
procedures and CSF leak occurred in 9% of revision cases versus 0.3% of primary cases 21.  Although 
it is felt that prior radiotherapy may contribute to increased morbidity, there was no difference in 
complications rates with prior radiotherapy in this series 21. 
Most reports in the literature on repeat transsphenoidal surgery focus on non-functioning adenoma 
resection rates and complications.  There are few data on biochemical remission rates for 
functioning adenomas after revision surgery.  Do et al reported biochemical remission in 75% of 12 
patients (7 GH secreting, 3 ACTH-secreting, 1 TSH-secreting and 1 prolactin-secreting), but did not 
use strict criteria of remission 19.  Moreover, Almeida et al reported biochemical remission in revision 
surgery for growth-hormone secreting adenoma in 63.6% using strict criteria of remission (80%  in 
microadenomas and 50% for macroadenomas), in 11 reoperations 24.  These results compare 
favourably to remission rates in first time surgery.  Almeida et al reported biochemical remission in 
acromegaly in 71.4% in first time surgery 24; however, meta-analysis of the published literature for 
functioning  adenoma remission rates show an overall biochemical remission rate of 66% 25.  
Similarly, for Cushing’s disease, Patil et al reported outcomes in 36 patients with Cushing’s disease 
undergoing repeat surgery, with 61% achieving remission 26.   
Improving pre-operative localisation of residual tumour 
The accurate identification of the functioning tumour target in recurrent disease is paramount to 
successful surgery. Standard imaging can be misleading in recurrent disease due to scar tissue and 
packing material used in prior operations.  Therefore, functional imaging such as positron emission 
tomography (PET) is an attractive modality to accurately localise functioning tissue.  By combining 
11C-methionine PET-CT with co-registered MRI, Koulouri et al found tracer uptake in 25 of 26 
patients with persistent acromegaly 27.  14 patients subsequently underwent repeat surgery, with 
confirmed GH secreting adenoma found at the corresponding site in 12 cases.  Similar results have 
been demonstrated in ACTH-secreting adenoma 28.  It is likely that PET-MRI will form the basis of 
decision-making in recurrent functioning adenoma in the future, reducing the need for blind 
fractionated radiotherapy to the whole sellar and parasellar region.  However, routine access to 11C-
Methionine PET imaging remains limited, but is rapidly increasing. 
Although the morbidity of repeat surgery is slightly higher than primary surgery, there is still 
substantial benefit in a significant proportion of patients with both functioning and non-functioning 
adenoma.  It is therefore our philosophy in the event of either tumour or biochemical recurrence to 
offer repeat surgery as the first option, unless the patient is unfit for surgery or there are anatomical 
reasons limiting the likelihood of success. 
What to do with the cavernous sinus? 
The cavernous sinus can be explored from a medial approach, viewing and entering the medial 
cavernous sinus wall endoscopically from within the sella (Figure 2).  Adenomas of Knosp grade 2-3 
can be completely resected in a significant proportion of cases 10.  The question of surgery for 
adenoma within the lateral compartment of the cavernous sinus is controversial.  As discussed, 
meaningful resection rates for Knosp grade 4 adenoma are poor 10.   It is possible to expose the 
lateral compartment, lateral to the carotid artery, from within the sphenoid sinus using an 
endoscopic approach.  However the lateral compartment contains the 6th cranial nerve free within 
the cavity and the 3rd, 4th and first division of the trigeminal nerve in the lateral wall.  Therefore 
surgery within this compartment carries significant risk of cranial nerve injury in addition to carotid 
injury.  The Pittsburgh group, who have the largest experience with expanded endoscopic surgery, 
have recently published their experience with cavernous sinus surgery for pituitary adenoma 29.  In 
this series the rate of gross total and near total resection of adenoma from the lateral compartment 
of the cavernous sinus was only 21%, with a complication rate of 6%, including 6th nerve palsy, post-
operative haematoma and a carotid injury.  Other centres report rates of 0% GTR with lateral 
cavernous sinus invasion 10,30 and 0% biochemical remission rates 30.  With such low rates of 
meaningful resection of tumour and the potential for long term cranial neuropathy, many centres 
consider alternative treatment options for residual disease in the lateral cavernous sinus, such as 
radiosurgery as first line.     
The effect of radiotherapy 
Radiotherapy is commonly used as second line treatment in functioning and non-functioning 
adenomas, for both tumour control and to achieve biochemical remission. All types of 
radiotherapy aim to deliver an effective treatment dose to gross tumour volume (residual or 
recurrent tumour) whilst limiting dose to surrounding normal tissues/structures.  
Radiotherapy techniques 
The radiation dose is usually delivered over 5 to 6 weeks in conventional radiotherapy (CRT) or 
over fewer fractions, (3 to 5) in hypo fractionated radiotherapy (HFRT) or single fraction, in 
stereotactic radiosurgery (SRS).  HFRT and SRS can be delivered using a variety of platforms 
(Gamma Knife, Cyber knife or Linear Accelerator).  CRT usually delivers a total dose of 45-50.4Gy in 
1.8 Gy per fraction and SRS delivers treatment dose (13-16Gy for non-functioning adenoma or 21-
25Gy in the case of secreting adenomas) in a single fraction.  
The linear accelerator based treatment planning involves acquisition of a dedicated CT scan 
acquired with thermoplastic shell head immobilization. The diagnostic MRI or planning MRI scan is 
fused with the CT scan to localise gross tumour volume. Modern radiation delivery techniques 
such as intensity modulated radiotherapy conforms treatment dose to target volumes better than 
CRT.  HFRT and SRS uses planning techniques to deliver high dose to target volume with sharp 
dose fall to surrounding normal structures, thereby reduce the volume of brain tissue irradiated to 
high radiation doses compared to CRT31. 
High energy proton beam therapy (PBT) due to its physical properties is able to spare more normal 
tissue compared to conventional x rays. Pituitary adenoma was one of first indications for PBT. 
Most reported series used passive scattering technique and a recent systematic review of PBT for 
intra cranial benign tumours in adults found it to be safe and effective in treating pituitary 
adenomas and could be used as an alternative to HFRT or SRS32.  PBT is becoming more widely 
available and carries the theoretical advantage of better dose distribution and normal tissue 
sparing, as yet there are limited data in pituitary adenoma and no evidence to suggest an 
advantage over conventional x rays 31.  PBT is currently recommended for suitable patients under 
age of 25 in the UK. 
The toxicity and dose to surrounding organs at risk (in particular normal pituitary gland and the 
optic apparatus) is dependent on tumour volume and its proximity to critical structures, which 
limits the use of SRS in clinical practice to smaller tumours that are at least 2 to 5mm away from 
optic apparatus.  For instance, to minimise the risk of radiation-induced visual decline, the tumour 
should be at least 2-5mm from the optic apparatus and the dose limited to 8 to 10 Gy.   
Radiotherapy Outcomes 
Radiotherapy is an effective treatment for non-functioning pituitary adenoma with reported  overall 
rates of long-term tumour control between 80-97% 33–35.  Traditionally, CRT has been used for large 
volume residual adenoma after surgery.   Minitti et al reported 5 and 10 year tumour control rates of 
97% and 91%, in a series of 68 patients with large residual tumours over 3cm 36.  When compared to 
post-operative observation alone, radiotherapy significantly improves tumour control from 68% for 
observation alone at 5 years to 93% 37.   
For small volume residual or tumour progression, SRS provides a more attractive alternative for 
patients, as it is usually a single day case treatment.  In a large series, Losa et al demonstrated a 
recurrence rate of 9.6% for recurrent non-functioning adenoma treated with SRS at a median of 78 
months 38.  In a retrospective study comparing the use of early SRS for residual tumour following 
surgery compared to delayed SRS (>6 months following surgery)39,  delayed SRS was associated with 
a higher risk of long term tumour recurrence (6.3% in the early group versus 28.1% in the delayed 
group, p=0.043).  Additionally, new onset endocrinopathy was demonstrated in 17% of the early SRS 
group versus 64% in the late cohort.  However, most of the new endocrinopathy in the delayed 
cohort occurred prior to SRS and was attributed to interval tumour progression, leading the authors 
to conclude that early SRS is superior.   
For functioning adenoma, both CRT and SRS may be used after failed surgery, with the aim of 
achieving biochemical remission.  However, remission rates after radiotherapy are much lower than 
radiological tumour control rates and are highly variable.  Remission rates for SRS in GH-secreting 
adenoma range from 35-100%.  However, using current stringent criteria of cure,  the average 
remission rate at 5 years is 48% 40.  Similarly, the biochemical remission rate for Cushing’s disease 
across 15 studies including 465 patients was 64% 40.  Despite the higher marginal doses used in 
secreting tumours, new onset hypopituitarism and optic nerve dysfunction are comparable to non-
functioning adenoma.   
The decision between CRT and SRS depends largely on the residual tumour volume and the distance 
from the optic apparatus.  A recent meta-analysis demonstrated no difference in biochemical 
remission rates between CRT and SRS 41.  Some authors suggest a faster rate of hormone 
normalisation after SRS 42,43.  However, many studies have demonstrated median times to 
normalisation between 30-66 months, similar to CRT, and show that time to normalisation is related 
to pre-irradiation hormone levels, not the method of radiation 44.  
Repeat irradiation for pituitary adenoma can be considered, for example using focal SRS where 
prior CRT has failed.   However, careful attention must be paid to the dose distribution to the 
temporal lobes as temporal lobe necrosis has been described following re-irradiation with both 
repeat CRT 45 and SRS 46.  Additionally there is a risk of radiation induced optic neuropathy that 
may be higher than in primary radiotherapy46. 
Early and late side-effects of pituitary radiotherapy – should early radiotherapy be avoided? 
For any technique, the use of adjuvant radiotherapy must be carefully balanced against the risks. 
In a large multicentre study of Gamma Knife radiosurgery for non-functioning pituitary adenoma, 
6.6% of patients developed new or worsened optic nerve dysfunction whilst new or worsened 
hypopituitarism occurred in 21% 47.  Therefore, the use of early radiotherapy to prevent future 
tumour recurrence or growth is controversial.  It is also important to remember that early post-
operative imaging can be misleading, with operative packing material or normal gland being 
interpreted as residual tumour.  
The risk of optic neuropathy varies from 1-5% with conventional RT and 1-4% in SRS, when the 
dose to the optic nerve is limited to <10Gy 48. Other cranial neuropathies are rare but there is a 
risk of brain necrosis in SRS when doses >20Gy are used 40.   
Hypopituitarism is a well-known complication of conventional RT for pituitary disease, reported to 
occur in 80% over 10 years 35. Different pituitary axes exhibit different radiosensitivity with GH 
deficiency occurring in 45-100%, followed by gonadotroph deficiency (30%), TSH deficiency (25%) 
and ACTH deficiency (22%)49.   Modern radiotherapy techniques aimed at sparing normal tissue 
(either IMRT or SRS) seem to be associated with lower rates of hypopituitarism between 10-40%. 
However, longer term follow up studies are lacking for newer techniques.  Hypopituitarism itself is 
associated with a two-fold increase in mortality rate, predominantly due to cerebrovascular events 
50.  Additionally, radiotherapy is associated with an increased risk of cerebrovascular events and 
cognitive decline 51.  Ischaemic stroke has not been reported as a complication of SRS 52, but longer 
follow up data is needed. 
RT also carries a risk of inducing a second intracranial tumour including glioma, sarcoma or 
meningioma.  Minniti et al report a cumulative risk of a second brain tumour of 2.4% at 20 years 53.  
However, the risk of inducing second tumours appears to be significantly less with SRS54 and PBT32.   
  
 
Multimodal therapy in aggressive pituitary tumours 
Where standard interventions fail, medical therapy or systemic chemotherapy is considered.  
Cabergoline has been used in non-functioning adenoma as treatment for post-operative residual 
tumour.  In a retrospective observational study, Greenman et al, reported  55 patients treated with 
cabergoline as preventative treatment following surgery; tumour control was achieved in 87% at 8 
years compared to 53% of controls 55.  Additionally, 42% of the control group required further 
surgery, compared to 13% of those treated with cabergoline.  However, randomised trials are 
lacking. Pasireotide has also been reported to be effective in some aggressive functioning tumours, 
including ACTH carcinomas, resistant somatotroph adenomas and prolactinoma 56–59, although 
experience is still minimal and the expense of treatment is likely to limit its use to only very selected 
cases.   
Temozolamide (TMZ) , an oral alkylating chemotherapy agent, has become widely used in clinically 
aggressive pituitary tumours and carcinomas, and is now recommended as first-line therapy after 
failure of conventional therapy 60.  First reported in 2006 61, subsequent reports with increasing 
numbers of patients have demonstrated a consistent response rate of approximately 69% in 
carcinomas and 60% in aggressive adenomas 62.  A survey of  European Society of Endocrinology 
members reported 166 patients treated with TMZ 63, of which 69% were functioning tumours (45% 
corticotroph adenomas).  After a median of 9 cycles, treatment response, including disease stability, 
was observed in 70%.  Patients with clinically functioning tumours and who received concomitant 
radiotherapy showed a better response.  However, of those with a partial response or stable 
disease, progression was seen in 40% and 48% respectively at a median of 12 months following 
treatment, reflecting the underlying tumour biology of these difficult-to-treat tumours63.  However, 
current guidance is based on small cohort studies and to date no randomized control trial has 
been undertaken.  Additionally all decisions regarding the use of TMZ should be undertaken with 
an oncologist in the setting of a multidisciplinary team (MDT).  
It is currently uncertain at which stage in the disease process TMZ should be considered and for 
what duration of treatment, particularly as concomitant radiotherapy appears beneficial.   In 
patients who progress after initial response to 6 months of TMZ, a further challenge with TMZ  is 
recommended 60. TMZ is generally well tolerated, fatigue is frequently reported and 
haematological toxicity may require drug withdrawal64. 
Current guidelines 
There are evidence based guidelines for the management of recurrent pituitary adenoma  and 
aggressive adenoma produced by North American and European groups 60,65.  Common to both is the 
recommendation that these tumours are managed by an MDT with dedicated pituitary surgeons 
(Table 6).   
The Congress of Neurological Surgeons’ guidelines are based on level 2 and 3 evidence and 
recommend early radiotherapy for post-operative residuum (either CRT or SRS), to reduce the risk of 
future progression.  However they acknowledge that this recommendation is based on limited 
evidence and state that the timing of radiation treatment after resection warrants further 
investigation. They also recommend repeat resection as the primary intervention for recurrent or 
residual adenoma, reserving CRT or SRS for cases where the risk of surgery is deemed high. 
The European Society of Endocrinology guidelines for the management of aggressive pituitary 
tumours also recommend repeat surgery by an expert pituitary surgeon prior to consideration of 
other treatment options, but suggest adjuvant RT for initial post-operative residuum only where 
there are clinical indicators of aggressive behaviour, such as tumour invasion or high ki-67 60.  
Temozolomide chemotherapy is recommended for aggressive pituitary tumours or pituitary 
carcinomas, where there is documented tumour growth, although this is based on low quality 
evidence.  There is also no recommendation of the stage in the course of the disease that TMZ 
should be considered.  Although both guidelines are based on low quality evidence, they provide a 
framework for current practice. 
 
Conclusion 
Aggressive pituitary tumours should be recognised early and a tailored treatment plan outlined.  It is 
our preference to consider early repeat surgery in most cases where possible, with the aim of 
maximal safe resection of tumour for long-term visual protection in non-functioning adenoma and 
biochemical remission in functioning adenoma.  Where possible, the aim is to preserve normal 
pituitary function and avoid radiotherapy, in order to reduce the incidence of long term 
hypopituitarism and reduce exposure to radiation.  Revision surgery is often better tolerated by 
patients than conventional fractionated radiotherapy.  In the majority of non-functioning adenomas, 
recurrence rates are low and the interval to recurrence relatively long, allowing for initial 
observation followed by repeat surgery for significant relapse.   
Given the low cure rates associated with non-surgical treatment of functioning adenoma (with the 
exception of prolactinoma), repeat surgery offers the best chance of endocrine remission.  Residual 
tumour should be sought on both thin slice MRI and (functional) PET imaging to identify a surgical 
target, and expanded approaches used where necessary in an attempt to achieve remission.  SRS can 
then be considered if repeat surgery fails or there is no evidence of residual tumour on imaging. 
Aggressive pituitary tumours often require multimodal therapy and repeat salvage interventions.  
The use of temozolomide is likely to increase, with earlier use in the course of the disease.  However, 
surgery plays a key role to minimise tumour burden and preserve neurological function, although 
repeat pituitary surgery remains challenging. 
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Tables 
Table 1: Modified Knosp grade of pituitary adenoma10. (CS, cavernous sinus) 
Knosp Grade Tumour Extension 
0 No extension beyond medial border of carotid artery. CS not 
involved 
1 Extends to but not beyond intercarotid line 
2 Extends to lateral border of carotid 
3A Extends beyond carotid in superior CS compartment 
3B Extends beyond carotid into inferior CS compartment 
4 Total encasement of the intracavernous carotid artery 
 
Table 2: Imaging markers of aggressive pituitary adenoma 
Imaging Markers of Aggressive Pituitary Adenoma 
Cavernous sinus invasion (Knosp Grade 3B  or 4) 
Clival bone invasion 
Sphenoid bone invasion 
T2 hyperintensity (sparsely granulated somatotroph) 
Early recurrence 
 
Table 3: Probability of recurrence of pituitary tumours 12 
Low probability of recurrence  High probability of recurrence  Malignant  
Pituitary adenoma  Adenoma with elevated Ki 67  Pituitary carcinoma  
 
Sparsely granulated somatotroph adenoma 
 
 
Lactotroph adenoma in men  
 
 
Silent corticotroph adenoma  
 
 
Crooke cell adenoma  
 
 
Plurihormonal PIT-1 positive adenoma  
 
 
 
 
 
Table 4: Indications for revision surgery 
Indications for revision pituitary surgery 
Prior subtotal resection with ongoing mass effect on optic apparatus 
Persistent elevated hormone level after failed pituitary surgery with tumour evident on MRI or  11-C 
Met PET imaging 
Recurrent tumour approaching optic apparatus 
Regrowth after prior radiotherapy 
Adenoma reduction to facilitate effective radiotherapy/radiosurgery 
 
Table 5: Current literature on endoscopic revision surgery for recurrent or residual adenoma, 
radiological outcomes and complications (GTR, gross total resection; DI, diabetes insipidus) 
Reference Total 
patients 
GTR (%) New 
hypopituitarism 
(%) 
New DI 
(%) 
CSF leak 
(%) 
Major 
complications 
19 61 51.7 14.7 4.9 4.9 3% 
haematoma 
66 41 58.5 9.8 4.9 2.4 2.4% 
haematoma 
67 27 63 3.7 7.4 0 3.7% 
abducens 
palsy 
21 48 - 7 35 9 0 
18 59 62.7 6.8 5 1.6 1.7% 
haematoma 
68 39 46 0 0 2.6 2.6% 
haematoma 
 
Table 6: Summary of current guidelines for management of recurrent pituitary adenoma from 
Congress of Neurological Surgeons (CNS) and European Society of Endocrinology (ESE)60,65 
Current  management guidelines for recurrent adenoma 
Dedicated pituitary surgeon opinion on revision surgery prior to adjuvant therapies 
Patients should be managed in the setting of an MDT 
Repeat resection for symptomatic recurrent or residual tumour 
SRS or CRT recommended for residual tumour (USA – upfront, Europe growing residual) 
Serial imaging after complete or near total resection 
Adjuvant radiotherapy should be considered for tumour remnant with biological features of 
aggression such as high proliferative index, aggressive tumour subtype 
 
Figure Legends 
Figure 1: Modified Knosp grade depicted on coronal MR imaging (a)Grade 0, white lines depict the 
medial and lateral aspect of the internal carotid artery (b) Grade 1 (c) Grade 2 (d) Grade 3A (e) Grade 
3B (f) Grade 4 
Figure 2: Medial cavernous sinus wall defect after tumour resection, viewed with a zero degree 
endoscopic transsphenoidal approach. 
 


